Sort   by:  
 Page size 
UnknownNeutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11,...
S-EPMC11797383 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain.

Objective

To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19.

Design, setting, and participants

In an ongoing adaptive platfor...
S-EPMC8941448 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Importance

The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.

Objective

To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.

Design, setting, and participants

S-EPMC9857594 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.

Background

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no stati...
S-EPMC10755839 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Importance

Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.

Objective

To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patien...
S-EPMC10326520 | biostudies-literature
Sort   by:  
 Page size